Home > Cluster Organisations > Biocat (Bioregion of Catalonia)

Biocat (Bioregion of Catalonia)

Primary tabs

Printer-friendly versionPrinter-friendly version
General Information
The date when the cluster organisation was established: 
Tuesday, 14 February, 2006
Number of staff in the management team of the cluster organisation : 
Cluster Excellence Label: 
Please Specify: 
EIT-Health Core Partner
Membership to European Strategic Cluster Partnerships (ESCP-4i, ESCP-S3 or ESCP-4x): 
Membership to other networks/partnerships: 
Cluster Management Team: 
Internationalisation Responsible
Cluster Manager
Project Manager
Languages spoken: 
Sectoral and Industrial Focus
Sectoral Industries: 
Education and Knowledge Creation
Technology fields: 
Medical Research
Pharmaceutical Products / Drugs
S3 EU priority areas: 
Human health activities (medical services)
Scientific research & development
Emerging industries: 
Medical Devices
Areas of specialisation of the cluster not covered above: 
Life Sciences & Health Care innovation
Composition of the cluster
Total number of members: 
Number of SME members: 
Number of start-ups among SME members: 
Number of larger company members: 
Number of research organisations/universities/technology centres: 
Entrepreneurship and scale-up support facilities in the cluster's ecosystem (see "Organisation type"): 
Name and link of major players: 
Cluster Strategy

Biocat is the institution that brings together the life sciences and healthcare innovation community in Catalonia.

Created in 2006 at the behest of the Government of Catalonia, Biocat’s mission is to maximize the economic and social impact of the life sciences and healthcare innovation of the BioRegion.

Biocat focuses its strategy on different key points:

  • Raising awareness and promoting the ecosystem, creating tools and strategies for improving the knowledge of the Catalan healthcare sector and increasing its projection both at home and abroad, with the aim of positioning the BioRegion as an international reference.
  • Providing innovative training and developing talent, by designing and executing programs and initiatives to improve talent and entrepreneurship considered essential factors for the growth of the sector.
  • Accelerating technology transfer and business growth by supporting and carrying out activities for increasing the value of the sector, placing special emphasis on the added value of research, knowledge and technology transfer, internationalization and access to capital.
Do you have a formalised strategy?: 
Do you have a specific strategy focus that addresses internationalisation ?: 
Support services provided: 
Internationalisation support (= Access to third countries markets)
Access to public support (regional/national programmes, innovation vouchers, etc.)
Facilitation of collaboration between members
Trend-scouting (Ideas for innovative projects)
Promotion of activities (marketing/ visibility)
Cooperation Activities
International Cooperation
The main countries targeted by the cluster organisation: 
United States
Our cluster organisation undertook the following international activities to support our members: 
Participation at missions/events/study visits/fairs
Trans-national Cooperation
The main countries targeted by the cluster organisation: 
United Kingdom
Our cluster organisation undertook the following trans-national activities to support our members: 
Participation at missions/events/study visits/fairs
Support Programmes
Participation in Funded Support Programmes: 
European ProgrammesProject NameLinkName & Description (Regional/National)Link (Regional/National)

bioXclusters+ 2016-2018

bioXclusters+  is a continuation of bioXclusters, first initiative funded by the EC from 2012 to 2014. The initiative gathers4 cluster partners: Biocat (Catalonia), BioM (Bavaria), bioPmed/Bioindustry Park Silvano Fumero (Piemonte) and Lyonbiopole (Rhône-Alpes, project leader), aiming to reinforce and promote international competitiveness of their SMEs on strategic global markets.

EIT Health 2015-2020

The European EIT Health project is a consortium with nodes in Barcelona, Paris (France), London (United Kingdom), Rotterdam (Benelux), Stockholm (Sweden/Denmark) and Heidelberg (Germany). It is comprised of more than 50 core partners and 90 associated partners from 14 countries in the European Union, all of which are committed to innovation in health and its impact on improving quality of life. Biocat, which has been working to promote this initiative since 2009, is an associate member of EIT Health and has participated actively in drafting and coordinating the proposal for the Spanish node.

BILAT USA 2.0 2012-2015

Bilat USA 2.0 is a project under the European Commission’s 7th Framework Program (7FP) that promotes cooperation in science, technology and innovation between Europe and the United States. In addition to Catalonia, eight other European countries and four prestigious American bodies are participating. 

Transbio SUDOE 2013-2015

Transbio SUDOE is the continuation of the Interbio project, aimed at uniting research centers, technology platforms, universities and companies in eight regions in Spain, France and Portugal in a multidisciplinary network to more effectively transform the results of biotechnology research into economic results. 

bioXclusters 2012-2013

bioXclusters was a project carried out with support from the European Union that aimed to boost and promote the international competitiveness of biotechnology SMEs in three strategic markets: the United States, China and Brazil. 

ETTBio 2012-2014

ETTBio was an Interreg IVC international cooperation program geared towards identifying, exchanging and sharing best practices for technology transfer in biotechnology with the final goal of improving regional policies in this area. It has ten partners from seven European regions. 

HealthTIES 2010-2013

HealthTIES was a consortium made up of four European regions that aimed to promote innovation in medical technology and bridge the gap between research in this area and patient needs. 

Interbio 2009-2012

Interbio was an interregional cooperation program that aimed to foster transnational cooperation, technology transfer and innovation in the fields of biotechnology and the life sciences in southwestern Europe. 

Bio-CT 2009-2011

Bio-CT aimed to valorize projects and create biotechnology companies. Participants included bodies from Germany, France, Hungary, Italy, the United Kingdom and Catalonia.

RIS3CAT communities bid

The Government of Catalonia is launching the RIS3CAT Communities, a pioneering strategy in Europe that aims to transform the business fabric in Catalonia through 2020. The initiative is the practical application of the RIS3CAT Smart Specialization Strategy, passed by the Catalan government last year in response to the directives established by the European Union in the Europe 2020 Strategy.

In this context, Biocat is coordinating and dynamizing the creation of a future RIS3CAT community in Innovation and Health, to address the main health-related challenges today. 

Relevant Project References: 
EIT Health, bioXclusters, Transbio SUDOE, d·Health Barcelona, ETTBio, Bilat USA 2.0,
Success Story / Achievements: 

One of Biocat’s main goals is to strengthen the BioRegion of Catalonia, to help the biocluster take a qualitative leap forward both nationally and internationally. This is why Biocat is working on a series of strategic projects on different levels. 

EIT Health, Biocat’s commitment to Europe, is a program devoted to innovation in health and its impact on improving quality of life. The Barcelona Clinical Trials Platform (BCTP) aims to position Catalonia among the top 5 areas in Spain for conducting clinical trials, bringing coordination, integration, quality and speed to clinical trials carried out here. 

Moreover, Biocat is also dynamizing and coordinating the creation of a future RIS3CAT community to address Catalonia’s main health-related challenges, from knowledge to market access. 

Why should partners choose you for cooperation?: 

From basic research to manufacturing and marketing new drugs or innovative medical devices, the whole biosciences sector is global, and the ability of Catalan companies to act and compete in this environment is key to their development and viability in the future.